Taysha Gene Therapies, Inc. (TSHA)
Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.
Address
3000 PEGASUS PARK DRIVE
DALLAS, TX 75247
Founded
2019
Number of Employees
52
Website
http://www.tayshagtx.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)